GINA 2021 – breakthrough or continuation? Review article

Article Sidebar

PDF (Język Polski)


Published: Aug 20, 2021
DOI: https://doi.org/10.24292/01.AP.173200821
Keywords:
GINA, asthma, treatment

Main Article Content

Adam J. Sybilski
1. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie. 2. Klinika Chorób Dziecięcych i Noworodkowych z Centrum Alergologii i Dermatologii, Centralny Szpital Kliniczny MSWiA w Warszawie
http://orcid.org/0000-0003-2389-277X

Abstract

Global Initiative for Asthma is an organization which activities are based on raising awareness of asthma among medical personnel, patients and the public, about its causes, course, treatment and impact of functioning. Its recommendations are based on scientific research, their successive update gave rise to the issue of new guidelines in 2019, which will be presented in the article. It is a continuation of the biggest changes in 30 years that occurred in 2019. The most important being the change in the therapeutic approach in stage first and second of disease. The main change is to limit the use of fast – acting β2-mimetics in monotherapy and to take combination medicines – inhalation glucocorticosteroids with bronchodilators (long-acting β2-agonists, short-acting β2-agonists).

Downloads

Download data is not yet available.

Article Details

How to Cite
Sybilski , A. J. (2021). GINA 2021 – breakthrough or continuation?. Alergoprofil, 17(3), 3-7. https://doi.org/10.24292/01.AP.173200821
Issue
Vol 17 No 3 (2021)
Section
THERAPY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Generoso A, Oppenheimer J. Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutics. Curr Opin Allergy Clin Immunol. 2020; 20(1): 43-7.
2. Global Strategy for Asthma Management and Prevention (2021 update) (access: 31.06.2021).
3. Hancox RJ, Cowan JO, Flannery EM et al. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000; 94: 767-71.
4. Mintz M, Gilsenan AW, Bui CL et al. Assessment of asthma control in primary care. Curr Med Res Opin. 2009; 25: 2523-31.
5. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J. 1994; 7: 1602-9.
6. Papi A, Canonica GW, Maestrelli P et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007; 356: 2040-52.
7. Busse WW, Pedersen S, Pauwel RA et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008; 121(5): 1167-74.
8. Reddel HK, Busse WW, Pedersen S et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017; 389: 157-66.